A year ago, Roche’s future in Alzheimer’s disease looked uncertain. At an Alzheimer’s conference in San Francisco, the pharmaceutical company announced that its amyloid-targeting antibody gantenerumab failed to slow cognitive decline in a pivotal 2,000-patient study. The degree of amyloid removal was unexpectedly low, and Roche halted ongoing…
Click here to view original post
